Crestor, Zocor Comparison May Be More Useful Than ASTEROID – Editorial
Executive Summary
A trial comparing high doses of AstraZeneca's Crestor and Merck's Zocor would be more informative than the open label, single-arm ASTEROID study evaluating the effects of high-intensity Crestor on regression of coronary atherosclerosis, according to an editorial in the March 13 issue of the Journal of the American Medical Association
You may also be interested in...
Cholesterol Playing Field Expands To Early Atherosclerosis, HDL, Novel Drugs
Pfizer is hoping to use the results of its failed torcetrapib trials as additional evidence of Lipitor's efficacy in halting progression of atherosclerosis, while competitor AstraZeneca offers new data to expand Crestor's use into early atherosclerosis
Cholesterol Playing Field Expands To Early Atherosclerosis, HDL, Novel Drugs
Pfizer is hoping to use the results of its failed torcetrapib trials as additional evidence of Lipitor's efficacy in halting progression of atherosclerosis, while competitor AstraZeneca offers new data to expand Crestor's use into early atherosclerosis
Zocor Generic Dose Dependence: Lipitor Aims High While Crestor Goes Low
Payers are targeting only the lowest dose of Pfizer's Lipitor in their efforts to switch patients to generic Zocor (simvastatin), Senior VP-Global Pharmaceutical Finance Peter Brandt said